Literature DB >> 19574928

Mouse models of fragile X-associated tremor ataxia.

Robert F Berman1, Rob Willemsen.   

Abstract

OBJECTIVE: To describe the development of mouse models of fragile X-associated tremor/ataxia (FXTAS) and the behavioral, histological and molecular characteristics of these mice.
METHOD: This paper compares the pathophysiology and neuropsychological features of FXTAS in humans to the major mouse models of FXTAS. Specifically, the development of a transgenic mouse line carrying an expanded CGG trinucleotide repeat in the 5'-untranslated region (5'-UTR) of the Fmr1 gene is described along with a description of the characteristic intranuclear ubiquitin-positive inclusions and the behavioral sequella observed in these mice.
RESULTS: CGG KI mice model many of the important features of FXTAS, although some aspects are not well modeled in mice. Aspects of FXTAS that are modeled well include elevated levels of Fmr1 mRNA, reduced levels of Fmrp, the presence of intranuclear inclusions that develop with age and show similar distributions within neurons, and neuropsychological and cognitive deficits, including poor motor function, impaired memory and evidence of increased anxiety. Features of FXTAS that are not well modeled in these mice include intentional tremors that are observed in some FXTAS patients but have not been reported in CGG KI mice. In addition, although intranuclear inclusions in astrocytes are very prominent in FXTAS, there are relatively few observed in CGG KI mice. A number of additional features of FXTAS have not been systematically examined in mouse models yet, including white matter disease, hyperintensities in T2-weighted magnetic resonance imaging, and brain atrophy, although these are currently under investigation in our laboratories.
CONCLUSIONS: The available mouse model has provided valuable insights into the molecular biology and pathophysiology of FXTAS and will be particularly useful for developing and testing new therapeutic treatments in the future.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19574928      PMCID: PMC2787904          DOI: 10.2310/JIM.0b013e3181af59d6

Source DB:  PubMed          Journal:  J Investig Med        ISSN: 1081-5589            Impact factor:   2.895


  34 in total

1.  FMR1 premutation allele (CGG)81 is stable in mice.

Authors:  C J Bontekoe; E de Graaff; I M Nieuwenhuizen; R Willemsen; B A Oostra
Journal:  Eur J Hum Genet       Date:  1997 Sep-Oct       Impact factor: 4.246

2.  Abnormal elevation of FMR1 mRNA is associated with psychological symptoms in individuals with the fragile X premutation.

Authors:  David Hessl; Flora Tassone; Danuta Z Loesch; Elizabeth Berry-Kravis; Maureen A Leehey; Louise W Gane; Ingrid Barbato; Cathlin Rice; Emma Gould; Deborah A Hall; James Grigsby; Jacob A Wegelin; Susan Harris; Foster Lewin; Dahlia Weinberg; Paul J Hagerman; Randi J Hagerman
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2005-11-05       Impact factor: 3.568

3.  Parkinsonism, dysautonomia, and intranuclear inclusions in a fragile X carrier: a clinical-pathological study.

Authors:  Elan Louis; Carol Moskowitz; Michael Friez; Maria Amaya; Jean Paul G Vonsattel
Journal:  Mov Disord       Date:  2006-03       Impact factor: 10.338

4.  The FMR1 CGG repeat mouse displays ubiquitin-positive intranuclear neuronal inclusions; implications for the cerebellar tremor/ataxia syndrome.

Authors:  Rob Willemsen; Marianne Hoogeveen-Westerveld; Surya Reis; Joan Holstege; Lies-Anne W F M Severijnen; Ingeborg M Nieuwenhuizen; Mariette Schrier; Leontine van Unen; Flora Tassone; Andre T Hoogeveen; Paul J Hagerman; Edwin J Mientjes; Ben A Oostra
Journal:  Hum Mol Genet       Date:  2003-05-01       Impact factor: 6.150

5.  Testicular and pituitary inclusion formation in fragile X associated tremor/ataxia syndrome.

Authors:  Claudia M Greco; Kultida Soontrapornchai; Juthamas Wirojanan; John E Gould; Paul J Hagerman; Randi J Hagerman
Journal:  J Urol       Date:  2007-04       Impact factor: 7.450

6.  Elevated Fmr1 mRNA levels and reduced protein expression in a mouse model with an unmethylated Fragile X full mutation.

Authors:  J R Brouwer; E J Mientjes; C E Bakker; I M Nieuwenhuizen; L A Severijnen; H C Van der Linde; D L Nelson; B A Oostra; R Willemsen
Journal:  Exp Cell Res       Date:  2006-10-13       Impact factor: 3.905

7.  Cognitive profile of fragile X premutation carriers with and without fragile X-associated tremor/ataxia syndrome.

Authors:  Jim Grigsby; Angela G Brega; Karen Engle; Maureen A Leehey; Randi J Hagerman; Flora Tassone; David Hessl; Paul J Hagerman; Jennifer B Cogswell; Rachael E Bennett; Kylee Cook; Deborah A Hall; Lanee S Bounds; Marsha J Paulich; Ann Reynolds
Journal:  Neuropsychology       Date:  2008-01       Impact factor: 3.295

8.  Altered hypothalamus-pituitary-adrenal gland axis regulation in the expanded CGG-repeat mouse model for fragile X-associated tremor/ataxia syndrome.

Authors:  J R Brouwer; E Severijnen; F H de Jong; D Hessl; R J Hagerman; B A Oostra; R Willemsen
Journal:  Psychoneuroendocrinology       Date:  2008-05-12       Impact factor: 4.905

9.  Long uninterrupted CGG repeats within the first exon of the human FMR1 gene are not intrinsically unstable in transgenic mice.

Authors:  C Lavedan; E Grabczyk; K Usdin; R L Nussbaum
Journal:  Genomics       Date:  1998-06-01       Impact factor: 5.736

10.  Regional FMRP deficits and large repeat expansions into the full mutation range in a new Fragile X premutation mouse model.

Authors:  Ali Entezam; Rea Biacsi; Bonnie Orrison; Tapas Saha; Gloria E Hoffman; Ed Grabczyk; Robert L Nussbaum; Karen Usdin
Journal:  Gene       Date:  2007-03-16       Impact factor: 3.688

View more
  34 in total

Review 1.  Neurodegeneration the RNA way.

Authors:  Abigail J Renoux; Peter K Todd
Journal:  Prog Neurobiol       Date:  2011-11-03       Impact factor: 11.685

2.  Signaling defects in iPSC-derived fragile X premutation neurons.

Authors:  Jing Liu; Katarzyna A Koscielska; Zhengyu Cao; Susan Hulsizer; Natalie Grace; Gaela Mitchell; Catherine Nacey; Jackline Githinji; Jeannine McGee; Dolores Garcia-Arocena; Randi J Hagerman; Jan Nolta; Isaac N Pessah; Paul J Hagerman
Journal:  Hum Mol Genet       Date:  2012-05-28       Impact factor: 6.150

3.  Abnormal dendrite and spine morphology in primary visual cortex in the CGG knock-in mouse model of the fragile X premutation.

Authors:  Robert F Berman; Karl D Murray; Gloria Arque; Michael R Hunsaker; H Jürgen Wenzel
Journal:  Epilepsia       Date:  2012-06       Impact factor: 5.864

Review 4.  Fragile X-associated tremor/ataxia syndrome (FXTAS): pathology and mechanisms.

Authors:  Paul Hagerman
Journal:  Acta Neuropathol       Date:  2013-06-21       Impact factor: 17.088

5.  Temporal ordering deficits in female CGG KI mice heterozygous for the fragile X premutation.

Authors:  Michael R Hunsaker; Naomi J Goodrich-Hunsaker; Rob Willemsen; Robert F Berman
Journal:  Behav Brain Res       Date:  2010-05-15       Impact factor: 3.332

Review 6.  What has been learned from mouse models of the Fragile X Premutation and Fragile X-associated tremor/ataxia syndrome?

Authors:  Molly M Foote; Milo Careaga; Robert F Berman
Journal:  Clin Neuropsychol       Date:  2016-06-29       Impact factor: 3.535

7.  Impaired activity-dependent FMRP translation and enhanced mGluR-dependent LTD in Fragile X premutation mice.

Authors:  Adam J Iliff; Abigail J Renoux; Amy Krans; Karen Usdin; Michael A Sutton; Peter K Todd
Journal:  Hum Mol Genet       Date:  2012-12-18       Impact factor: 6.150

8.  CNS expression of murine fragile X protein (FMRP) as a function of CGG-repeat size.

Authors:  Anna Lisa Ludwig; Glenda M Espinal; Dalyir I Pretto; Amanda L Jamal; Gloria Arque; Flora Tassone; Robert F Berman; Paul J Hagerman
Journal:  Hum Mol Genet       Date:  2014-01-23       Impact factor: 6.150

9.  Ubiquitin-positive intranuclear inclusions in neuronal and glial cells in a mouse model of the fragile X premutation.

Authors:  H Jürgen Wenzel; Michael R Hunsaker; Claudia M Greco; Rob Willemsen; Robert F Berman
Journal:  Brain Res       Date:  2010-01-04       Impact factor: 3.252

10.  Fragile X and autism: Intertwined at the molecular level leading to targeted treatments.

Authors:  Randi Hagerman; Gry Hoem; Paul Hagerman
Journal:  Mol Autism       Date:  2010-09-21       Impact factor: 7.509

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.